← Scroll for more →
Traws Pharma, Inc. (TRAW)
Pharmaceutical Preparations
Latest Price
$0.37
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
0.11
P/B Ratio
3.28
Valuation metrics
adjust assumptions →EPS: $0.82
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$12.30
+3506% upside
Institutional Ownership
40.3% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 1.20M | $1.0M | 7.88% | +597.7K | 2026-06-30 |
| Ally Bridge Group (NY) LLC | 786.2K | -- | 5.15% | -- | 2026-06-30 |
| Adage Capital Partners GP, L.L.C. | 730.0K | -- | 4.78% | -- | 2026-06-30 |
| ADAR1 Capital Management, LLC | 597.7K | -- | 3.92% | +443.6K | 2026-06-30 |
| Lynx1 Capital Management LP | 559.5K | -- | 3.67% | +544.4K | 2026-06-30 |
| Ikarian Capital, LLC | 478.1K | -- | 3.13% | -200.0K | 2026-06-30 |
| Sphera Funds Management Ltd. | 398.5K | -- | 2.61% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 330.0K | -- | 2.16% | +274.9K | 2026-06-30 |
| Jane Street Group, LLC | 216.0K | -- | 1.42% | +194.8K | 2026-06-30 |
| Alyeska Investment Group, L.P. | 164.4K | -- | 1.08% | +111.7K | 2026-06-30 |